NasdaqGS:EXEL

Stock Analysis Report

Executive Summary

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.

Snowflake

Fundamentals

Outstanding track record with flawless balance sheet.


Similar Companies

Share Price & News

How has Exelixis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

14.6%

NasdaqGS:EXEL

0.5%

US Biotechs

-0.7%

US Market


1 Year Return

28.0%

NasdaqGS:EXEL

-8.0%

US Biotechs

-0.5%

US Market

EXEL outperformed the Biotechs industry which returned -8% over the past year.

EXEL outperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

EXELIndustryMarket
7 Day14.6%0.5%-0.7%
30 Day6.5%1.0%-3.0%
90 Day10.9%3.2%0.9%
1 Year28.0%28.0%-7.3%-8.0%1.7%-0.5%
3 Year98.0%98.0%9.3%5.6%39.5%30.4%
5 Year452.4%452.4%7.7%2.7%54.1%37.0%

Price Volatility Vs. Market

How volatile is Exelixis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Exelixis undervalued based on future cash flows and its price relative to the stock market?

10.6x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Exelixis's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Exelixis's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Exelixis is good value based on earnings compared to the US Biotechs industry average.

Exelixis is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Exelixis is good value based on expected growth next year.


Price Based on Value of Assets

Exelixis is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Exelixis expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

17.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Exelixis's revenue is expected to grow by 14.7% yearly, however this is not considered high growth (20% yearly).

Exelixis's earnings are expected to grow by 17.9% yearly, however this is not considered high growth (20% yearly).

Exelixis's revenue growth is expected to exceed the United States of America market average.

Exelixis's earnings growth is expected to exceed the United States of America market average.

Exelixis's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Exelixis is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Exelixis performed over the past 5 years?

75.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Exelixis has delivered over 20% year on year earnings growth in the past 5 years.

Exelixis's 1-year earnings growth exceeds its 5-year average (98.6% vs 75%)

Exelixis's earnings growth has exceeded the US Biotechs industry average in the past year (98.6% vs 78.4%).


Return on Equity

Exelixis made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Exelixis used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Exelixis has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Exelixis's financial position?


Financial Position Analysis

Exelixis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Exelixis's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Exelixis's level of debt (0%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (13572.1% vs 0% today).

Debt is well covered by operating cash flow (1.584051096935E+19%, greater than 20% of total debt).

Exelixis earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.6944107703135E+17x debt.


Next Steps

Dividend

What is Exelixis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Exelixis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Exelixis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Exelixis has not reported any payouts.

Unable to verify if Exelixis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Exelixis has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Exelixis's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Exelixis's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Michael Morrissey (58yo)

9.1yrs

Tenure

US$7,977,535

Compensation

Dr. Michael M. Morrissey, Ph.D., has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development at Exelixis Inc. sin ...


CEO Compensation Analysis

Michael's remuneration is about average for companies of similar size in United States of America.

Michael's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.1yrs

Average Tenure

58yo

Average Age

The tenure for the Exelixis management team is about average.


Board Age and Tenure

16.9yrs

Average Tenure

65.5yo

Average Age

The average tenure for the Exelixis board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,018,00011 May 19
Lance Willsey
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares50,000
Max PriceUS$20.36
SellUS$750,60304 May 19
Christopher Senner
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares36,261
Max PriceUS$20.70
SellUS$95,13728 Feb 19
Patrick Haley
EntityIndividual
Shares4,272
Max PriceUS$22.27
SellUS$5,494,90620 Feb 19
Charles Cohen
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares248,180
Max PriceUS$22.41
SellUS$285,29001 Dec 18
Jeffrey Hessekiel
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares14,818
Max PriceUS$19.91
SellUS$173,18301 Dec 18
Christopher Senner
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares8,791
Max PriceUS$19.70
SellUS$346,40010 Nov 18
Patrick Haley
EntityIndividual
Shares20,000
Max PriceUS$17.32
SellUS$421,25026 Sep 18
George Scangos
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares25,000
Max PriceUS$16.85

Ownership Breakdown


Management Team

  • Gisela Schwab (62yo)

    President of Product Development & Medical Affairs and Chief Medical Officer

    • Tenure: 13.5yrs
    • Compensation: US$3.60m
  • Stelios Papadopoulos (71yo)

    Co-Founder & Chairman

    • Tenure: 21.6yrs
    • Compensation: US$421.05k
  • Michael Morrissey (58yo)

    CEO, President & Director

    • Tenure: 9.1yrs
    • Compensation: US$7.98m
  • Peter Lamb (58yo)

    Executive VP of Scientific Strategy & Chief Scientific Officer

    • Tenure: 12.6yrs
    • Compensation: US$3.17m
  • Susan Hubbard

    Executive Vice President of Public Affairs & Investor Relations

    • Tenure: 2.7yrs
  • Jeffrey Hessekiel (50yo)

    Executive VP

    • Tenure: 5.5yrs
    • Compensation: US$2.73m
  • Chris Senner (51yo)

    Executive VP & CFO

    • Tenure: 4.1yrs
    • Compensation: US$3.39m
  • Jon Berndt

    Vice President of Sales

    • Tenure: 3.9yrs
  • Gregg Bernier

    Vice President of Marketing

    • Tenure: 3.9yrs
  • Dana Aftab

    Executive Vice President of Business Operations

    • Tenure: 3.5yrs

Board Members

  • Jack Wyszomierski (63yo)

    Independent Director

    • Tenure: 15.5yrs
    • Compensation: US$406.05k
  • Charlie Cohen (68yo)

    Independent Director

    • Tenure: 23.8yrs
    • Compensation: US$408.70k
  • Stelios Papadopoulos (71yo)

    Co-Founder & Chairman

    • Tenure: 21.6yrs
    • Compensation: US$421.05k
  • Michael Morrissey (58yo)

    CEO, President & Director

    • Tenure: 9.1yrs
    • Compensation: US$7.98m
  • George Poste (75yo)

    Independent Director

    • Tenure: 15.0yrs
    • Compensation: US$396.05k
  • Lance Willsey (57yo)

    Independent Director

    • Tenure: 22.3yrs
    • Compensation: US$384.70k
  • George Scangos (71yo)

    Independent Director

    • Tenure: 22.8yrs
    • Compensation: US$375.70k
  • Vincent Marchesi (83yo)

    Independent Director

    • Tenure: 18.3yrs
    • Compensation: US$391.05k
  • Alan Garber (63yo)

    Independent Director

    • Tenure: 14.6yrs
    • Compensation: US$390.70k
  • José Baselga (59yo)

    Member of Scientific Advisory Board

    • Tenure: 12.6yrs

Company Information

Exelixis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Exelixis, Inc.
  • Ticker: EXEL
  • Exchange: NasdaqGS
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.861b
  • Shares outstanding: 302.91m
  • Website: https://www.exelixis.com

Number of Employees


Location

  • Exelixis, Inc.
  • 1851 Harbor Bay Parkway
  • Alameda
  • California
  • 94502
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXELNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2000
EX9DB (Deutsche Boerse AG)YesCommon StockDEEURApr 2000
0IJOLSE (London Stock Exchange)YesCommon StockGBUSDApr 2000

Biography

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products includ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 23:35
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.